Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Jeffrey S. Flier Sells 20,316 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) Director Jeffrey S. Flier sold 20,316 shares of the firm's stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $32.24, for a total transaction of $654,987.84. Following the completion of the transaction, the director now owns 24,070 shares in the company, valued at $776,016.80. This represents a 45.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Scholar Rock Stock Up 0.9%

Scholar Rock stock traded up $0.33 on Friday, hitting $35.81. 1,735,708 shares of the stock traded hands, compared to its average volume of 1,302,043. The company has a current ratio of 10.25, a quick ratio of 10.25 and a debt-to-equity ratio of 0.16. The firm has a market cap of $3.40 billion, a P/E ratio of -14.15 and a beta of 0.28. The business's fifty day simple moving average is $32.11 and its 200 day simple moving average is $35.75. Scholar Rock Holding Corporation has a 1 year low of $6.76 and a 1 year high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same quarter last year, the firm earned ($0.59) earnings per share. As a group, sell-side analysts forecast that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Institutional Trading of Scholar Rock

Institutional investors and hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC grew its holdings in shares of Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock valued at $39,000 after buying an additional 766 shares during the last quarter. CWM LLC boosted its stake in Scholar Rock by 152.8% during the 1st quarter. CWM LLC now owns 996 shares of the company's stock valued at $32,000 after purchasing an additional 602 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Scholar Rock in the fourth quarter worth $85,000. Federated Hermes Inc. purchased a new position in shares of Scholar Rock in the first quarter worth $71,000. Finally, Strs Ohio bought a new position in shares of Scholar Rock during the first quarter valued at $77,000. 91.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

SRRK has been the subject of a number of research analyst reports. Lifesci Capital raised Scholar Rock to a "strong-buy" rating in a research note on Tuesday, June 3rd. Wedbush reaffirmed an "outperform" rating and issued a $50.00 price target on shares of Scholar Rock in a research note on Wednesday, June 18th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $42.67.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.